Ex vivo and in vitro screening and expansion of immune cells of a patient with capacities for immunotherapy
2017
University of British Columbia, Vancouver, Canada
The success of several forms of immunotherapy depends entirely on the presence of mutated cancer antigens, or neoantigens. Adoptive cell therapy (ACT) against neoantigens will require reliable methods to isolate and expand rare, neoantigen-specific T cells from clinically available biospecimens. In the present study, the researchers used in vitro screening of small quantities of peripheral blood from multiple time points from an ovarian cancer patient to recognize peptides corresponding to
the patient's tumor somatic mutation. The researchers identified different T cell lines, which collectively recognized mutations peptides. Some lines could be expanded ex vivo from peripheral blood prior to the first tumor recurrence. Thus, neoantigen-specific T cells can be expanded from small volumes of blood during tumor remission, making pre-emptive ACT a plausible clinical strategy.
A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer
Brad H. Nelson
Added on: 07-29-2021
[1] https://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1371895[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
